FDA Grants Approval to New Fixed-Dose Combination of Perjeta and Herceptin
Genentech announced the FDA granted approval to Phesgo, a new fixed-dose combination of Perjeta and Herceptin available in a single vial. It can be administered under the skin (subcutaneous injection) in just minutes, significantly reducing the amount of time a patient spends receiving treatment when compared to hours with IV administration. The Genentech press release including Important Safety Information is linked here and the FDA release is linked here.
The approval is important because this marks the first time that Genentech has combined two cancer medicines into a single formulation.
Visit Genentech’s breast cancer page on Gene.com to learn more about our approach to breast cancer.
